The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir ...

Scientists say the drug stops the virus from replicating inside cells. The landmark deal to provide cheaper antiretroviral ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

Global health groups will provide backing for two generic manufacturers to produce and distribute a low-cost version of a new ...

Gilead's groundbreaking HIV prevention drug will soon be available at a fraction of its U.S. price in over 100 countries, ...

Cheap generic versions of a groundbreaking HIV-prevention jab should be available in more than 100 countries from 2027, ...

HIV (human immunodeficiency virus) remains a significant global health challenge, affecting millions of people worldwide. While advancements in medical science have led to better management of the ...

Lenacapavir is a long-acting HIV medication known as a capsid inhibitor. It works by blocking the virus's protective shell, ...

Avoidable HIV infections and net health care costs would rise if coverage of pre-exposure prophylaxis (PrEP) were to be reduced even a moderate amount, according to a study published in JAMA Network ...

A decline in PrEP coverage could reverse HIV prevention gains, causing tens of thousands of preventable infections and billions in added healthcare costs, a new JAMA Network Open study finds.

The South Carolina Department of Public Health (DPH) is observing its sixth annual PrEP (pre-exposure prophylaxis) Awareness ...

South Carolina Department of Public Health offering free HIV testing during PrEP Awareness Week September 22-26 ...